Literature DB >> 30730272

The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.

Daniel J Olson1, Jason J Luke.   

Abstract

Entities:  

Keywords:  cancer immunology; checkpoint inhibitors; clinical immunology; clinical trial design; immunotherapy

Mesh：

Substances：

Year:  2019        PMID： 30730272      PMCID： PMC7226703          DOI： 10.2217/imt-2018-0171

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  15 in total

Review 1.  TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity.

Authors:  Gordon J Freeman; Jose M Casasnovas; Dale T Umetsu; Rosemarie H DeKruyff
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 2.  Radiotherapy and immunotherapy: a beneficial liaison?

Authors:  Ralph R Weichselbaum; Hua Liang; Liufu Deng; Yang-Xin Fu
Journal:  Nat Rev Clin Oncol       Date:  2017-01-17       Impact factor: 66.675

Review 3.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

4.  Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Authors:  Jason J Luke; Jeffrey M Lemons; Theodore G Karrison; Sean P Pitroda; James M Melotek; Yuanyuan Zha; Hania A Al-Hallaq; Ainhoa Arina; Nikolai N Khodarev; Linda Janisch; Paul Chang; Jyoti D Patel; Gini F Fleming; John Moroney; Manish R Sharma; Julia R White; Mark J Ratain; Thomas F Gajewski; Ralph R Weichselbaum; Steven J Chmura
Journal:  J Clin Oncol       Date:  2018-02-13       Impact factor: 44.544

5.  Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice.

Authors:  Sally M Amos; Hollie J Pegram; Jennifer A Westwood; Liza B John; Christel Devaud; Chris J Clarke; Nicholas P Restifo; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Cancer Immunol Immunother       Date:  2011-02-16       Impact factor: 6.968

6.  The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.

Authors:  Byron C Burnette; Hua Liang; Youjin Lee; Lukasz Chlewicki; Nikolai N Khodarev; Ralph R Weichselbaum; Yang-Xin Fu; Sogyong L Auh
Journal:  Cancer Res       Date:  2011-02-07       Impact factor: 12.701

7.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.

Authors:  Helena Harlin; Yuru Meng; Amy C Peterson; Yuanyuan Zha; Maria Tretiakova; Craig Slingluff; Mark McKee; Thomas F Gajewski
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

8.  Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Authors:  Fernando Ulloa-Montoya; Jamila Louahed; Benjamin Dizier; Olivier Gruselle; Bart Spiessens; Frédéric F Lehmann; Stefan Suciu; Wim H J Kruit; Alexander M M Eggermont; Johan Vansteenkiste; Vincent G Brichard
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

Review 9.  The host STING pathway at the interface of cancer and immunity.

Authors:  Leticia Corrales; Sarah M McWhirter; Thomas W Dubensky; Thomas F Gajewski
Journal:  J Clin Invest       Date:  2016-07-01       Impact factor: 14.808

10.  LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

Authors:  Joseph F Grosso; Cristin C Kelleher; Timothy J Harris; Charles H Maris; Edward L Hipkiss; Angelo De Marzo; Robert Anders; George Netto; Derese Getnet; Tullia C Bruno; Monica V Goldberg; Drew M Pardoll; Charles G Drake
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808
View more
  6 in total

Review 1.  Immunogenic cell death in colon cancer prevention and therapy.

Authors:  Hang Ruan; Brian J Leibowitz; Lin Zhang; Jian Yu
Journal:  Mol Carcinog       Date:  2020-03-25       Impact factor: 4.784

Review 2.  WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.

Authors:  Xin Li; Yanwei Xiang; Fulun Li; Chengqian Yin; Bin Li; Xisong Ke
Journal:  Front Immunol       Date:  2019-09-26       Impact factor: 7.561

3.  CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas.

Authors:  Depei Li; Wanming Hu; Xiaoping Lin; Ji Zhang; Zhenqiang He; Sheng Zhong; Xia Wen; Peiyu Zhang; Xiaobing Jiang; Hao Duan; Chengcheng Guo; Jian Wang; Jing Zeng; Zhongping Chen; Yonggao Mou; Ke Sai
Journal:  Front Cell Dev Biol       Date:  2021-03-19

4.  Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib.

Authors:  Zhou Zhu; Nicholas C Turner; Sherene Loi; Fabrice André; Miguel Martin; Véronique Diéras; Karen A Gelmon; Nadia Harbeck; Cathy Zhang; Joan Q Cao; Zhengming Yan; Dongrui R Lu; Ping Wei; Todd L VanArsdale; Paul A Rejto; Xin Huang; Hope S Rugo; Sibylle Loibl; Massimo Cristofanilli; Richard S Finn; Yuan Liu
Journal:  NPJ Precis Oncol       Date:  2022-08-16

5.  The epiphany derived from T-cell-inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses.

Authors:  Decao Niu; Yifeng Chen; Hua Mi; Zengnan Mo; Guijian Pang
Journal:  Front Genet       Date:  2022-08-11       Impact factor: 4.772

Review 6.  WNT Signaling in Melanoma.

Authors:  Anna Gajos-Michniewicz; Malgorzata Czyz
Journal:  Int J Mol Sci       Date:  2020-07-09       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.